ResMed (RMD) Stock Forecast & Price Target

$241.99 +0.44 (+0.18%)

(As of 01:30 PM ET)

ResMed - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 12 Analyst Ratings

Sell
1

Hold
5

Buy
6

Based on 12 Wall Street analysts who have issued ratings for ResMed in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 1 has given a sell rating, 5 have given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for RMD.

Consensus Price Target

$225.70
-6.73% Downside

According to the 12 analysts' twelve-month price targets for ResMed, the average price target is $225.70. The highest price target for RMD is $283.00, while the lowest price target for RMD is $180.00. The average price target represents a forecasted downside of -6.73% from the current price of $241.99.

Get the Latest News and Ratings for RMD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for ResMed and its competitors.

RMD Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)	9 Buy rating(s)
Hold	5 Hold rating(s)	5 Hold rating(s)	5 Hold rating(s)	3 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$225.70	$218.18	$204.70	$202.33
Forecasted Upside	-6.73% Downside	-9.08% Downside	-9.68% Downside	32.58% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)

The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…

Claim your FREE 2024 Gold Guide

RMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

ResMed Stock vs. The Competition

Type	ResMed	Medical Companies	S&P 500
Consensus Rating Score	2.50	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	-6.73% Downside	27,416.78% Upside	8.80% Upside
News Sentiment Rating	Positive News See Recent RMD News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/25/2024	KeyCorp 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$251.00 ➝ $266.00	+3.55%
10/25/2024	Royal Bank of Canada 4 of 5 stars		Boost Target	Sector Perform ➝ Sector Perform	$224.00 ➝ $232.00	-9.68%
10/25/2024	Needham & Company LLC 3 of 5 stars	M. Matson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold
10/25/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$280.00 ➝ $283.00	+18.39%
9/26/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$240.00 ➝ $270.00	+11.12%
9/24/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Rescott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
Trump won. Buy this coin now. (Ad) Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher. This could be his favorite coin.
9/18/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Polark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Peer Perform ➝ Underperform	$180.00	-28.25%
6/25/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
6/24/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Chevrier Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
3/27/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$215.00	+9.88%
1/25/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$175.00 ➝ $180.00	-3.41%
1/9/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$160.00 ➝ $195.00	+7.32%
10/27/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight	$180.00 ➝ $169.00	+21.82%
10/5/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$240.00 ➝ $165.00	+11.49%
1/31/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Kaczor Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 01:55 PM ET.

Should I Buy ResMed Stock? RMD Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, November 4, 2024. Please send any questions or comments about these ResMed pros and cons to contact@marketbeat.com.

ResMed
Bull Case

Here are some ways that investors could benefit from investing in ResMed Inc.:

ResMed Inc. has consistently increased its dividend payouts, indicating financial stability and potential for income generation for investors. The current annualized dividend yield of 0.89% is attractive for income-focused investors.
Analysts have set a new price target for ResMed Inc. at $213.75, suggesting potential for stock price appreciation based on market expectations.
Institutional investors have been actively increasing their stakes in ResMed Inc., signaling confidence in the company's growth prospects and financial performance.
ResMed Inc. has a diverse product portfolio in the healthcare markets, particularly in Sleep and Respiratory Care, which are essential and growing segments in the healthcare industry.
The company's EPS expectations for the current year are positive at 8.97, indicating strong earnings potential and financial health.

ResMed
Bear Case

Investors should be bearish about investing in ResMed Inc. for these reasons:

ResMed Inc.'s stock price has been volatile in recent periods, which may pose risks for short-term investors looking for stable returns.
There is a sell rating from one investment analyst on ResMed Inc., suggesting some concerns about the company's performance or market conditions.
While the company has a moderate buy consensus rating, there are also hold ratings, indicating mixed opinions from analysts on the stock's future performance.
Insiders have been actively selling shares of ResMed Inc. in the last 90 days, which could raise questions about internal confidence in the company's growth trajectory.
ResMed Inc.'s payout ratio of 32.57% may limit future dividend growth potential, impacting income-focused investors in the long term.

RMD Forecast - Frequently Asked Questions

: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for ResMed is $225.70, with a high forecast of $283.00 and a low forecast of $180.00.
: 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There is currently 1 sell rating, 5 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RMD shares.
: According to analysts, ResMed's stock has a predicted downside of -6.73% based on their 12-month stock forecasts.
: Over the previous 90 days, ResMed's stock had 1 upgrade and 1 downgrade by analysts.
: ResMed has been rated by research analysts at Baird R W, Bank of America, KeyCorp, Needham & Company LLC, Robert W. Baird, Royal Bank of Canada, and Wolfe Research in the past 90 days.
: Analysts like ResMed less than other "medical" companies. The consensus rating score for ResMed is 2.50 while the average consensus rating score for "medical" companies is 2.80. Learn more on how RMD compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

When it comes to NVDA… “acceleration cycles” are the key (Ad)

Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.

Use this link to see Nvidia Unchained right away!

This page (NYSE:RMD) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ResMed (RMD) Stock Forecast & Price Target